Professional Statements and Societal Positions Guidelines
National Comprehensive Cancer Network (NCCN)-2021
Myelodysplastic Syndromes – v.1.2.2022 – 2021
Allogeneic HCT from an HLA-matched sibling, matched unrelated, or alternative donor is a preferred approach for treating select individuals with MDS, particularly those with high-risk disease. This includes both standard and RIC strategies.
Myeloproliferative Neoplasms – v.2.2021 - 2021
Allogeneic HCT is the only potentially curative treatment option resulting in long-term remissions for individuals with MF. However, the use of myeloablative conditioning is associated with higher rates of non-relapse mortality (NRM).